CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, for steroid‐dependent Crohn's disease: a randomized, double‐blind, placebo‐controlled trial

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2006-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.2006.02791.xPMID 16480401
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• From the authors

  2005cited by this paper
• A randomized, double‐blind, placebo‐controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, in patients with corticosteroid‐dependent Crohn's disease

  2005cited by this paper
• A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.

  2005cited by this paper
• Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

  2004cited by this paper
• CDP 571 , a humanised monoclonal antibody to tumour necrosis factor a , for moderate to severe Crohn ’ s disease : a randomised , double blind , placebo controlled trial

  2004cited by this paper
• CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

  2004cited by this paper
• CDP571, a humanized monoclonal antibody to TNF-α, a well tolerated alternative in Crohn's disease patients who have experienced hypersensitivity reactions to infliximab

  2003cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

  2003cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.

  2001cited by this paper
• The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.

  2001cited by this paper
• [A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators].

  2000cited by this paper
• A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

  2000cited by this paper
• A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.

  2000cited by this paper
• Infliximab for the treatment of fistulas in patients with Crohn's disease.

  1999cited by this paper
• Methotrexate treatment for Crohn's disease.

  1998cited by this paper
• Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease

  1997cited by this paper
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

  1997cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

  1997cited by this paper
• Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.

  1997cited by this paper
• Does self-administration of a quality of life index for inflammatory bowel disease change the results?

  1996cited by this paper
• Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.

  1995cited by this paper
• A controlled double blind study of azathioprine in the management of Crohn's disease.

  1995cited by this paper
• Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses.

  1995cited by this paper
• Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group.

  1994cited by this paper
• Humanized antibodies.

  1993cited by this paper
• Humanized antibodies.

  1993cited by this paper
• National Cooperative Crohn's Disease Study: results of drug treatment.

  1979cited by this paper
• Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

  1976cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Assessment of outcomes in Crohn's disease: A systematic review of randomized clinical trials to inform a multiple outcome framework

  2024cites this paper
• Is it time to include older adults in inflammatory bowel disease trials? A call for action.

  2022cites this paper
• Therapy for Crohn's Disease

  2019cites this paper
• Systematic review: outcomes and adverse events from randomised trials in Crohns disease

  2019cites this paper
• Systematic review: outcomes and adverse events from randomised trials in Crohn's disease

  2019cites this paper
• A New Venue of TNF Targeting

  2018cites this paper
• Antitumor Necrosis Factor Agents in Crohn’s Disease

  2018cites this paper
• Systematic review with meta‐analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease

  2018influential citation
• Cost-effectiveness modelling for benefit-risk assessment

  2018cites this paper
• Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review

  2018cites this paper
• Systematic review with meta‐analysis: placebo rates in induction and maintenance trials of Crohn's disease

  2017cites this paper
• Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.

  2017cites this paper
• Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease.

  2016cites this paper
• IL-32θ gene expression in acute myeloid leukemia suppresses TNF-α production

  2015cites this paper
• Biologic agents for IBD: practical insights

  2015cites this paper
• TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future.

  2014cites this paper
• Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease.

  2014cites this paper
• The Increasing Weight of Crohn's Disease Subjects in Clinical Trials: A Hypothesis-generatings Time-trend Analysis

  2013influential citation
• Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro

  2012cites this paper
• Absorption, Distribution, Metabolism, and Excretion (ADME) Studies of Biotherapeutics for Autoimmune and Inflammatory Conditions

  2012cites this paper
• The safety of anti-tumor necrosis factor-alpha agents used for the treatment of inflammatory bowel disease: a systematic review and meta-analysis

  2012cites this paper
• Chapter five Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro

  2011cites this paper
• Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.

  2011cites this paper
• Cytokine blockade in inflammatory bowel diseases.

  2011cites this paper
• DIFFERENTIAL REGULATION OF INTERLEUKIN-17 AND INTERFERON- PRODUCTION IN INFLAMMATORY BOWEL DISEASE

  2011cites this paper
• Enteral nutrition feeding strategies and their impact on relapse rate and quality of life in paediatric Crohn's disease

  2010cites this paper
• TNF-α and its inhibitors in cancer

  2010cites this paper
• RETRACTED ARTICLE: Mechanisms and Efficacy of Immunobiologic Therapies for Inflammatory Bowel Diseases

  2010cites this paper
• Crohn's Disease

  2010cites this paper
• Anti-TNF α antibodies induce regulatory macrophages in an Fc region dependent manner

  2010cites this paper
• Biological therapy of inflammatory bowel disease.

  2009cites this paper
• Antagonists of TNF action: clinical experience and new developments

  2009influential citation
• Biologic Therapies For Inflammatory Bowel Disease

  2009cites this paper
• Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

  2008cites this paper
• Immunologic and Biochemical Factors of Coincident Celiac Disease and Type 1 Diabetes Mellitus in Children

  2008cites this paper
• Meta‐analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn’s disease

  2008cites this paper
• Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

  2008cites this paper
• Novel therapeutic options in the inflammatory bowel disease world.

  2008cites this paper
• Monoclonal antibodies as innovative therapeutics.

  2008cites this paper
• Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance.

  2007cites this paper
• Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments.

  2007cites this paper
• Treatment with biologic therapies and the risk of cancer in patients with IBD

  2007cites this paper
• Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease

  2007cites this paper
• Adalimumab in patients with Crohn’s disease – safety and efficacy in an open‐label single centre study

  2007cites this paper
• Treatment of Crohn’s disease with certolizumab pegol

  2007cites this paper
• Current and future anti-TNF therapy for inflammatory bowel disease

  2007cites this paper
• Inflammatory bowel disease: clinical aspects and established and evolving therapies

  2007cites this paper
• Novel biological therapies for inflammatory bowel disease

  2006cites this paper
• Current World Literature

  2006cites this paper